PAVmed Inc. (PAVM)
PAVmed Inc.
360 Madison Avenue
25th Floor
New York, NY 10017
United States
212 949 4319
https://www.pavmed.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 107
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Lishan Aklog M.D. | Chairman & CEO | 945.09k | N/D | 1966 |
| Mr. Dennis M. McGrath CPA | President, CFO & Corporate Secretary | 663.38k | N/D | 1957 |
| Mr. Shaun M. O'Neill M.B.A. | Executive VP & COO | 447.47k | N/D | 1983 |
| Dr. Brian J. deGuzman M.D. | Executive VP, Chief Technology & Compliance Officer | 427.6k | N/D | 1965 |
| Dr. Suman M. Verma M.D., Ph.D. | Senior VP of Molecular Genetics & Chief Scientific Officer | N/D | N/D | N/D |
| Michael Parks | Vice President of Investor Relations | N/D | N/D | N/D |
| Mr. Michael Adam Gordon | Executive VP, General Counsel & Secretary | N/D | N/D | 1974 |
| Dr. Deepika A. Lakhani Ph.D. | Senior VP, Chief Regulatory & Quality Officer | N/D | N/D | N/D |
| Dr. Victoria T. Lee M.D. | Senior VP & Chief Medical Officer | N/D | N/D | N/D |
Descripción
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de PAVmed Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
